IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Special Investigation of Kaletra in Pregnant Women
This study has been completed.
Sponsor:
Abbott
Information provided by (Responsible Party):
Abbott
ClinicalTrials.gov Identifier:
NCT01076985
First received: February 25, 2010
Last updated: December 9, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This non-interventional, post-marketing observational study was conducted to obtain safety data from the use of lopinavir/ritonavir (Kaletra), in clinical practice, in pregnant women and their children in Japan.
| Condition | Intervention |
|---|---|
| Human Immunodeficiency Virus | Drug: Lopinavir/ritonavir (Kaletra) |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Special Investigation of Kaletra in Pregnant Women |
Resource links provided by NLM:
Further study details as provided by Abbott:
Primary Outcome Measures:
- Number of Patients With Adverse Drug Reactions (ADRs) [ Time Frame: During pregnancy and for one year after birth ]The number of patients (mothers and infants) with adverse drug reactions, defined as adverse events for which the causal relationship with Kaletra was something other than "not related" by the investigator (i.e., "probable," "possible," or "unclear"). ADRs are reported by preferred term and inclusive of all those reported at any visit. Although a patient may experience a particular preferred term more than once, each patient was counted only once for each preferred term.
| Enrollment: | 24 |
| Study Start Date: | December 2000 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Lopinavir/ritonavir group
All pregnant women in this noninterventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
|
Drug: Lopinavir/ritonavir (Kaletra)
Lopinavir/ritonavir (LPV/r) evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
Other Names:
|
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Hospital
Criteria
Inclusion Criteria:
- All pregnant women who have received Kaletra for the treatment of HIV infection were eligible for this study
Exclusion Criteria:
-
Contraindications according to the Package Insert:
- Patients with a history of hypersensitivity to any ingredient of Kaletra
- Patients who are receiving pimozide, cisapride, ergotamine tartrate, dihydroergotamine mesylate, ergometrine maleate, methylergometrine maleate, midazolam, triazolam, vardenafil hydrochloride hydrate, boriconazol
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01076985
Please refer to this study by its ClinicalTrials.gov identifier: NCT01076985
Locations
| Japan | |
| Site Reference ID/Investigator# 35862 | |
| Aichi, Japan | |
| Site Reference ID/Investigator# 35863 | |
| Okayama, Japan | |
| Site Reference ID/Investigator# 35864 | |
| Osaka, Japan | |
| Site Reference ID/Investigator# 35865 | |
| Tokyo, Japan | |
| Site Reference ID/Investigator# 5326 | |
| Tokyo, Japan | |
Sponsors and Collaborators
Abbott
Investigators
| Study Director: | Toshiro Maeda | Abbott Japan Co.,Ltd |
More Information
| Responsible Party: | Abbott |
| ClinicalTrials.gov Identifier: | NCT01076985 History of Changes |
| Other Study ID Numbers: |
PMOS-JAP-00-002 |
| Study First Received: | February 25, 2010 |
| Results First Received: | December 9, 2011 |
| Last Updated: | December 9, 2011 |
Keywords provided by Abbott:
|
Human Immunodeficiency Virus |
Additional relevant MeSH terms:
|
Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Immune System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Ritonavir |
Lopinavir HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors |
ClinicalTrials.gov processed this record on September 21, 2017